Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ABBV
$220.08
$-4.05
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Next Earnings
2026-01-11
Beta
0.35
Average Volume
5765709
Market Cap
388929165998
Last Dividend
6.92
CIK
0001551152
ISIN
US00287Y1091
CUSIP
00287Y109
CEO
Robert A. Michael
Sector
Healthcare
Industry
Drug Manufacturers - General
Full Time Employees
55000
IPO Date
2013-01-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| MoneyShow's Best Investment Ideas For 2026: Part 1 | MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 1 of this series includes AbbVie, Alexandria Real Estate Equities, Arbor Realty Trust, Archer Aviation, and Ares Management Corp., among others. | Seeking Alpha | 2026-01-10 09:30:00 |
| 2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio | AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers. | The Motley Fool | 2026-01-09 11:45:00 |
| Merck Eyes Revolution Medicines in a Potential $32 Billion Deal | Merck (MRK) is reportedly in talks to acquire Revolution Medicines (RVMD) for $28-$32 billion or more. This acquisition aims to strengthen MRK's oncology pipeli | GuruFocus | 2026-01-09 11:14:00 |
| Here's What We Expect From AbbVie's Immunology Segment in Q4 | ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity. | Zacks Investment Research | 2026-01-09 08:46:08 |
| First Look: GM's $7.1B EV Charge, Paramount's $30 WBD Bid | Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us | GuruFocus | 2026-01-09 07:38:00 |
| Clear Harbor Asset Management LLC Decreases Stake in AbbVie Inc. $ABBV | Clear Harbor Asset Management LLC trimmed its position in shares of AbbVie Inc. (NYSE: ABBV) by 7.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,583 shares of the company's stock after selling 2,797 shares during the period. Clear Harbor Asset Management LLC's | Defense World | 2026-01-09 05:34:49 |
| Ferguson Wellman Capital Management Inc. Purchases 3,260 Shares of AbbVie Inc. $ABBV | Ferguson Wellman Capital Management Inc. increased its position in AbbVie Inc. (NYSE: ABBV) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 647,685 shares of the company's stock after acquiring an additional 3,260 shares during the period. AbbVie makes | Defense World | 2026-01-09 05:34:46 |
| AbbVie Inc. $ABBV Shares Bought by Duncker Streett & Co. Inc. | Duncker Streett and Co. Inc. lifted its position in AbbVie Inc. (NYSE: ABBV) by 17.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,277 shares of the company's stock after buying an additional 10,721 shares during the | Defense World | 2026-01-09 04:52:46 |
| Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight | Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion. | Benzinga | 2026-01-09 01:52:38 |
| AbbVie: The Dividend Does Not Lie | AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x. | Seeking Alpha | 2026-01-08 12:07:31 |
| AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. | Shareholders in both drugmakers appear disappointed that a deal may not happen. | Barrons | 2026-01-08 07:38:00 |
| Breakfast News: Defense Stocks Whipsaw | Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more | Fool - Investing News | 2026-01-08 07:30:00 |
| AbbVie Inc. $ABBV Stock Holdings Increased by CX Institutional | CX Institutional lifted its holdings in AbbVie Inc. (NYSE: ABBV) by 30.8% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 85,402 shares of the company's stock after purchasing an additional 20,097 shares during the quarter. CX Institutional's holdings in AbbVie were | Defense World | 2026-01-08 05:04:57 |
| Why Revolution Medicines Shares Are Sliding After Hours On Wednesday | Shares of Revolution Medicines tumbled in after-hours trading on Wednesday after AbbVie denied reports that it was in talks to acquire the cancer-drug developer. | Benzinga | 2026-01-08 03:13:05 |
| AbbVie in talks to buy biotech Revolution Medicines, WSJ reports | AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter. | Reuters | 2026-01-07 14:58:28 |
| AbbVie Near Deal for Revolution Medicines | The cancer-drug biotech firm has a market value around $16 billion. | WSJ | 2026-01-07 14:48:00 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. | Zacks Investment Research | 2026-01-07 09:55:19 |
| AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call | NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. | PRNewsWire | 2026-01-07 08:00:00 |
| AbbVie Inc. $ABBV Shares Acquired by Cerity Partners LLC | Cerity Partners LLC boosted its position in shares of AbbVie Inc. (NYSE: ABBV) by 0.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,137,257 shares of the company's stock after purchasing an additional 5,121 shares during the | Defense World | 2026-01-07 05:32:44 |
| What Can Trigger A Breakout In Abbvie Stock? | AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024. | Forbes | 2026-01-06 11:43:07 |
| AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know | The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close. | Zacks Investment Research | 2026-01-05 18:45:47 |
| AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference | NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. | PRNewsWire | 2026-01-05 08:00:00 |
| Railway Pension Investments Ltd Raises Holdings in AbbVie Inc. $ABBV | Railway Pension Investments Ltd raised its stake in shares of AbbVie Inc. (NYSE: ABBV) by 33.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 853,949 shares of the company's stock after purchasing an additional 211,800 shares during the quarter. AbbVie accounts | Defense World | 2026-01-05 07:21:04 |
| Commonwealth Equity Services LLC Cuts Holdings in AbbVie Inc. $ABBV | Commonwealth Equity Services LLC lessened its position in shares of AbbVie Inc. (NYSE: ABBV) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,130,248 shares of the company's stock after selling 74,586 shares during the period. | Defense World | 2026-01-05 05:10:44 |
| AbbVie Inc. $ABBV Holdings Raised by CWA Asset Management Group LLC | CWA Asset Management Group LLC grew its stake in shares of AbbVie Inc. (NYSE: ABBV) by 39.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,640 shares of the company's stock after acquiring an additional 20,264 shares during | Defense World | 2026-01-05 04:26:43 |
| 26 Top Dividend Stocks to Buy and Hold in 2026 | Another year, another long list of great dividend stocks. | Fool - Investing News | 2026-01-05 03:45:00 |
| AbbVie: Rocky Near-Term, Positive Long-Term | AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical sector as MFN agreements were signed, its revenue growth was strong and earnings surpassed expectations. However, elevated forward P/E, potential MFN-driven profit pressure, and a market shift favoring cyclicals over defensives, can impact it negatively in 2026. | Seeking Alpha | 2026-01-04 09:04:10 |
| AbbVie Inc. $ABBV Holdings Lifted by Capital Advisors Inc. OK | Capital Advisors Inc. OK increased its holdings in AbbVie Inc. (NYSE: ABBV) by 10.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 381,648 shares of the company's stock after acquiring an additional 34,548 shares during the period. | Defense World | 2026-01-04 04:18:53 |
| My Most Important Warning To Dividend Investors For 2026 | The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens the link between fiscal and monetary policy, amplifying market complexity. Artificially subdued long-term bond supply likely keeps long-term yields lower than they would be with more balanced issuance. | Seeking Alpha | 2026-01-03 07:30:00 |
| Buying This Healthcare Stock Could Make You a Millionaire Retiree | AbbVie has a solid business capable of performing well even in bad times. The company has proven that it can navigate challenges thanks to its innovative engine. | The Motley Fool | 2026-01-03 06:08:00 |
| Bell Bank Sells 10,943 Shares of AbbVie Inc. $ABBV | Bell Bank lessened its position in shares of AbbVie Inc. (NYSE: ABBV) by 15.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,248 shares of the company's stock after selling 10,943 shares during the period. AbbVie makes up | Defense World | 2026-01-03 05:04:51 |
| Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth | ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth. | Zacks Investment Research | 2026-01-02 08:46:05 |
| Generali Asset Management SPA SGR Decreases Stock Holdings in AbbVie Inc. $ABBV | Generali Asset Management SPA SGR lessened its stake in AbbVie Inc. (NYSE: ABBV) by 7.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 78,122 shares of the company's stock after selling 6,172 shares during the period. Generali Asset Management SPA SGR's | Defense World | 2026-01-02 06:18:43 |
| Financial Consulate Inc. Takes $731,000 Position in AbbVie Inc. $ABBV | Financial Consulate Inc. bought a new stake in AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,159 shares of the company's stock, valued at approximately $731,000. A number of other institutional investors | Defense World | 2026-01-02 04:27:12 |
| Banque Pictet & Cie SA Has $77.33 Million Stock Position in AbbVie Inc. $ABBV | Banque Pictet and Cie SA grew its stake in shares of AbbVie Inc. (NYSE: ABBV) by 89.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 333,971 shares of the company's stock after buying an additional 157,480 shares during the quarter. AbbVie makes | Defense World | 2026-01-02 03:34:54 |
| AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026 | AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compelling if earnings materialize, with technicals supporting a bullish breakout. Risks include Humira revenue erosion, pipeline uncertainty, and debt burden, but ABBV's clean loss-of-exclusivity profile and robust FCF yield support GARP status. | Seeking Alpha | 2026-01-01 22:24:10 |
| This 4% Bond ETF Matures in 2026, Then Returns Your Principal | Individual corporate bonds typically require $1,000 minimum purchases and leave retail investors stuck with whatever credit quality and maturity dates they can access through their broker. Invesco BulletShares 2026 Corporate Bond ETF (NYSEARCA:BSCQ) solves this by packaging investment-grade corporate bonds with a defined 2026 maturity into a single ETF trading around $19.60 per share, delivering... This 4% Bond ETF Matures in 2026, Then Returns Your Principal. | 247 Wallst | 2026-01-01 07:35:54 |
| Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Zacks Investment Research | 2025-12-31 10:00:47 |
| Best Dividend Aristocrats For January 2026 | The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts. | Seeking Alpha | 2025-12-31 08:47:58 |
| Diversified Trust Co Purchases 10,891 Shares of AbbVie Inc. $ABBV | Diversified Trust Co increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 23.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,076 shares of the company's stock after acquiring an additional 10,891 shares during the period. Diversified Trust Co's holdings | Defense World | 2025-12-31 06:16:44 |
| Calamos Wealth Management LLC Has $3.41 Million Position in AbbVie Inc. $ABBV | Calamos Wealth Management LLC grew its stake in AbbVie Inc. (NYSE: ABBV) by 74.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,729 shares of the company's stock after acquiring an additional 6,298 shares during the quarter. Calamos | Defense World | 2025-12-31 05:34:47 |
| 3 No-Brainer Dividend Stocks to Buy Right Now | AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. | The Motley Fool | 2025-12-30 15:05:00 |
| 3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains | Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns. | Zacks Investment Research | 2025-12-30 09:01:12 |
| Annex Advisory Services LLC Purchases 2,731 Shares of AbbVie Inc. $ABBV | Annex Advisory Services LLC increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 4.8% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,241 shares of the company's stock after acquiring an additional 2,731 shares during the quarter. Annex | Defense World | 2025-12-30 03:20:54 |
| Permanent Capital Management LP Makes New Investment in AbbVie Inc. $ABBV | Permanent Capital Management LP purchased a new stake in AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,109 shares of the company's stock, valued at approximately $720,000. Other hedge funds have also modified their holdings of the | Defense World | 2025-12-29 08:22:43 |
| Perigon Wealth Management LLC Purchases 3,905 Shares of AbbVie Inc. $ABBV | Perigon Wealth Management LLC lifted its stake in AbbVie Inc. (NYSE: ABBV) by 3.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 111,108 shares of the company's stock after purchasing an additional 3,905 shares during the quarter. Perigon Wealth Management LLC's holdings | Defense World | 2025-12-29 07:46:46 |
| AbbVie Inc. $ABBV Shares Sold by Sapient Capital LLC | Sapient Capital LLC cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 3.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 219,951 shares of the company's stock after selling 8,543 shares during the period. AbbVie comprises about 0.8% | Defense World | 2025-12-29 06:28:45 |
| Sowell Financial Services LLC Sells 8,716 Shares of AbbVie Inc. $ABBV | Sowell Financial Services LLC lowered its position in AbbVie Inc. (NYSE: ABBV) by 14.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,225 shares of the company's stock after selling 8,716 shares during the period. Sowell Financial | Defense World | 2025-12-29 06:28:44 |
| Mayflower Financial Advisors LLC Buys 3,414 Shares of AbbVie Inc. $ABBV | Mayflower Financial Advisors LLC boosted its stake in AbbVie Inc. (NYSE: ABBV) by 21.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,098 shares of the company's stock after purchasing an additional 3,414 shares during the quarter. Mayflower Financial Advisors | Defense World | 2025-12-29 05:46:46 |
| Best Dividend Kings: December 2025 | Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%. | Seeking Alpha | 2025-12-28 06:44:14 |
| AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of “Moderate Buy” by Brokerages | Shares of AbbVie Inc. (NYSE: ABBV - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-four analysts that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and three have issued a strong buy recommendation | Defense World | 2025-12-28 02:14:52 |
| 2 Dividend Stocks to Double Up On Right Now | Consumer staples and healthcare can be durable industries to invest in. Costco is highly profitable and relies on its proven membership model. | The Motley Fool | 2025-12-27 15:45:00 |
| Is AbbVie a Buy, Sell, or Hold in 2026? | AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected. | The Motley Fool | 2025-12-27 14:30:00 |
| The Best Stocks to Invest $50,000 in Right Now | Amazon and Alphabet are key leaders in the AI race on top of their flagship businesses. Walmart benefits from consistent non-discretionary spending like groceries. | The Motley Fool | 2025-12-27 13:30:00 |
| The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio | AbbVie headlines today's top stock reports as Zacks highlights pharma recovery, resilient beverages and Chevron???s evolving energy outlook. | Zacks Investment Research | 2025-12-26 02:56:06 |
| AbbVie Inc. $ABBV Shares Purchased by Brookstone Capital Management | Brookstone Capital Management boosted its stake in AbbVie Inc. (NYSE: ABBV) by 25.9% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 97,713 shares of the company's stock after purchasing an additional 20,100 shares during the period. Brookstone Capital Management's holdings in AbbVie were worth $22,624,000 | Defense World | 2025-12-25 05:34:41 |
| AbbVie Inc. $ABBV Shares Bought by Global X Japan Co. Ltd. | Global X Japan Co. Ltd. increased its position in AbbVie Inc. (NYSE: ABBV) by 587.7% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 25,664 shares of the company's stock after purchasing an additional 21,932 shares during the period. AbbVie accounts for about 0.5% of Global | Defense World | 2025-12-25 04:48:48 |
| Chatham Capital Group Inc. Has $6.49 Million Stake in AbbVie Inc. $ABBV | Chatham Capital Group Inc. trimmed its holdings in AbbVie Inc. (NYSE: ABBV) by 8.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,011 shares of the company's stock after selling 2,440 shares during the quarter. AbbVie comprises 0.9% of Chatham Capital Group | Defense World | 2025-12-25 04:48:48 |
| AbbVie Inc. $ABBV Shares Sold by Exchange Traded Concepts LLC | Exchange Traded Concepts LLC lessened its position in shares of AbbVie Inc. (NYSE: ABBV) by 45.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,612 shares of the company's stock after selling 34,825 shares during the period. Exchange Traded Concepts LLC's | Defense World | 2025-12-24 04:08:54 |
| ABBV vs. AZN: Which Pharma Stock is the Better Investment Now? | AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge. | Zacks Investment Research | 2025-12-23 11:56:10 |
| 5 Big Drug Stocks That May Continue to Outperform in 2026 | Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026. | Zacks Investment Research | 2025-12-23 09:51:10 |
| 2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now | When inflation drops, as we saw in the November consumer price index report, the Federal Reserve typically continues to cut interest rates, making fixed-income alternatives less attractive. | 24/7 Wall Street | 2025-12-23 07:42:20 |
| AbbVie Inc. $ABBV Shares Bought by Sara Bay Financial | Sara Bay Financial grew its stake in AbbVie Inc. (NYSE: ABBV) by 21.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,179 shares of the company's stock after purchasing an additional 3,002 shares during the period. AbbVie comprises | Defense World | 2025-12-22 05:56:49 |
| Foster Victor Wealth Advisors LLC Raises Stock Position in AbbVie Inc. $ABBV | Foster Victor Wealth Advisors LLC increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 4.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 79,462 shares of the company's stock after acquiring an additional 3,209 shares during the period. AbbVie makes | Defense World | 2025-12-22 05:56:47 |
| Charles Schwab Trust Co Acquires 15,502 Shares of AbbVie Inc. $ABBV | Charles Schwab Trust Co raised its holdings in AbbVie Inc. (NYSE: ABBV) by 93.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,105 shares of the company's stock after buying an additional 15,502 shares during the period. Charles Schwab Trust Co's holdings | Defense World | 2025-12-22 05:12:52 |
| AbbVie Inc. $ABBV is CHICAGO TRUST Co NA’s 8th Largest Position | CHICAGO TRUST Co NA trimmed its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 10.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,632 shares of the company's stock after selling 7,129 shares during the period. AbbVie makes | Defense World | 2025-12-22 05:12:52 |
| Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever | AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years. | The Motley Fool | 2025-12-22 04:44:00 |
| 3 Dividend Growth Stocks Analysts Are Upgrading for 2026 | A single analyst's rating and price target, the consensus rating and price target, for that matter, have little value to investors without the proper context. The context is the sentiment strength and trend, which for stocks like PepsiCo NASDAQ: PEP, AbbVie NYSE: ABBV, and United Parcel Service NYSE: UPS, is strong and bullish. | MarketBeat | 2025-12-21 09:23:12 |
| AbbVie Inc. $ABBV Shares Sold by BDF Gestion | BDF Gestion lessened its position in AbbVie Inc. (NYSE: ABBV) by 17.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,522 shares of the company's stock after selling 7,178 shares during the quarter. AbbVie makes up 0.9% of BDF Gestion's investment portfolio, | Defense World | 2025-12-21 03:54:42 |
| Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal | Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing. | Benzinga | 2025-12-20 01:38:01 |
| Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc | Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2 | GuruFocus | 2025-12-19 16:01:00 |
| Trump to announce new drug-pricing deals later today | The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. | Market Watch | 2025-12-19 10:45:00 |
| Is AbbVie a Millionaire Maker? | AbbVie is a pharmaceutical company with a focus on immunology, oncology, neuroscience, and aesthetics. The company's third-quarter earnings were down materially year over year, but it raised its full-year guidance. | The Motley Fool | 2025-12-18 16:30:00 |
| Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market. | Invest in stocks with good fundamentals, solid growth prospects, and steady dividends. These blue chip stocks have strong businesses that generate consistently strong results. | The Motley Fool | 2025-12-18 13:45:00 |
| Retirees Banking on Quarterly Income Choose HDV Over Growth Funds for Its Defensive Holdings | When income matters more than growth, retirees turn to funds that deliver quarterly checks without volatility. The iShares Core High Dividend ETF (NYSEARCA:HDV) yields 3.3%, triple the S&P 500's 1.03%. That difference translates to predictable cash flow for investors who need their portfolio to pay bills. Built for Income, Not Speculation HDV tracks 75 U.S.... Retirees Banking on Quarterly Income Choose HDV Over Growth Funds for Its Defensive Holdings. | 247 Wallst | 2025-12-18 09:03:18 |
| AbbVie Inc. $ABBV Shares Sold by Carolina Wealth Advisors LLC | Carolina Wealth Advisors LLC lessened its stake in shares of AbbVie Inc. (NYSE: ABBV) by 98.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 620 shares of the company's stock after selling 38,267 shares during the quarter. | Defense World | 2025-12-18 05:58:48 |
| Grant Private Wealth Management Inc Sells 8,979 Shares of AbbVie Inc. $ABBV | Grant Private Wealth Management Inc cut its position in AbbVie Inc. (NYSE: ABBV) by 75.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,915 shares of the company's stock after selling 8,979 shares during the quarter. Grant Private Wealth Management Inc's | Defense World | 2025-12-18 04:56:41 |
| Acropolis Investment Management LLC Has $1.62 Million Position in AbbVie Inc. $ABBV | Acropolis Investment Management LLC raised its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 115.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company's stock after purchasing an additional 3,746 shares during the quarter. Acropolis | Defense World | 2025-12-18 03:52:55 |
| AbbVie, several other pharma companies near MFN deal with Trump, sources say | AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation. | Reuters | 2025-12-17 16:11:16 |
| Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc | Market movers: The Investment Committee's top stocks to watch right now. | CNBC Television | 2025-12-17 14:17:18 |
| Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Zacks Investment Research | 2025-12-17 10:01:07 |
| How AbbVie's Pipeline Is Lining Up Key Product Launches | ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions. | Zacks Investment Research | 2025-12-16 10:02:08 |
| AbbVie Inc. $ABBV Shares Purchased by GAMMA Investing LLC | GAMMA Investing LLC grew its stake in shares of AbbVie Inc. (NYSE: ABBV) by 8.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,159 shares of the company's stock after acquiring an additional 4,633 shares during the quarter. | Defense World | 2025-12-16 06:16:43 |
| Gilbert Capital Group Inc. Takes Position in AbbVie Inc. $ABBV | Gilbert Capital Group Inc. purchased a new position in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 3,824 shares of the company's stock, valued at approximately $710,000. A number of other large investors also recently bought and sold | Defense World | 2025-12-16 05:32:59 |
| Rep. Julie Johnson Sells Off Shares of AbbVie Inc. (NYSE:ABBV) | Representative Julie Johnson (D-Texas) recently sold shares of AbbVie Inc. (NYSE: ABBV). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on November 13th. The trade occurred in the Representative's "CHASE BROKERAGE ACCOUNT (3935)" account. Representative Julie Johnson also recently made the following trade(s): | Defense World | 2025-12-15 05:38:43 |
| Caldwell Trust Co Takes Position in AbbVie Inc. $ABBV | Caldwell Trust Co bought a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 25,110 shares of the company's stock, valued at approximately $4,661,000. Several other hedge funds have also added | Defense World | 2025-12-15 03:52:52 |
| AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings | Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk. | Seeking Alpha | 2025-12-14 23:30:00 |
| My Top 3 Healthcare Stocks to Buy in 2026 | With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas. | The Motley Fool | 2025-12-13 14:37:00 |
| 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine | Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. | 24/7 Wall Street | 2025-12-13 12:26:47 |
| Why Ditching Schwab U.S. Dividend Equity ETF In the AI Era Is a Mistake | The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriented investments. At the same time, dividend-focused funds like the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) have faced scrutiny for lagging behind broader indices dominated by AI-driven companies. Schwab U.S. Dividend Equity ETF... Why Ditching Schwab U.S. Dividend Equity ETF In the AI Era Is a Mistake. | 247 Wallst | 2025-12-13 10:10:04 |
| Adage Capital Partners GP L.L.C. Lowers Position in AbbVie Inc. $ABBV | Adage Capital Partners GP L.L.C. decreased its stake in AbbVie Inc. (NYSE: ABBV) by 10.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,618,841 shares of the company's stock after selling 179,892 shares during the quarter. | Defense World | 2025-12-13 04:32:48 |
| Ameriprise Financial Inc. Sells 3,127,890 Shares of AbbVie Inc. $ABBV | Ameriprise Financial Inc. decreased its stake in AbbVie Inc. (NYSE: ABBV) by 25.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,267,451 shares of the company's stock after selling 3,127,890 shares during the quarter. Ameriprise Financial Inc. | Defense World | 2025-12-13 03:58:54 |
| Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026 | One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff. | The Motley Fool | 2025-12-12 12:23:00 |
| AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock | AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling. | Zacks Investment Research | 2025-12-12 08:46:13 |
| Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks | Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. | 24/7 Wall Street | 2025-12-12 07:22:40 |
| Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul | The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough. | MarketBeat | 2025-12-12 07:07:57 |
| The Smartest Dividend Stocks to Buy With $5,000 Right Now | Bank of America's low payout ratio means this is a dividend you can count on. AbbVie's raking in money with immunology drugs Skyrizi and Rinvoq. | The Motley Fool | 2025-12-12 04:00:00 |
| Is AbbVie Stock Too Cheap to Ignore at Today's Price? | Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. | The Motley Fool | 2025-12-11 11:06:00 |
| Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth | ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth. | Zacks Investment Research | 2025-12-11 08:51:04 |
| AbbVie: Unique Mix Of Growth And Value | AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s. ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and supporting strong EPS prospects. | Seeking Alpha | 2025-12-10 20:01:55 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 10-Q | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-10-31 | 2025-10-31 | View Filing |
| 8-K | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 10-Q | 2025-08-04 | 2025-08-04 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| 3/A | 2025-07-30 | 2025-07-30 | View Filing |
| 3 | 2025-07-11 | 2025-07-11 | View Filing |
| SC 13G/A | 2025-07-07 | 2025-07-07 | View Filing |
| 8-K | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 11-K | 2025-06-13 | 2025-06-13 | View Filing |
| SD | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 3 | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-12 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| ARS | 2025-03-25 | 2025-03-24 | View Filing |
| DEFA14A | 2025-03-24 | 2025-03-24 | View Filing |
| DEF 14A | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| PRE 14A | 2025-03-10 | 2025-03-10 | View Filing |
| 3 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| 424B5 | 2025-02-20 | 2025-02-20 | View Filing |
| 8-K | 2025-02-19 | 2025-02-19 | View Filing |
| FWP | 2025-02-19 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G | 2025-02-18 | 2025-02-18 | View Filing |
| 424B5 | 2025-02-18 | 2025-02-18 | View Filing |
| S-3ASR | 2025-02-14 | 2025-02-14 | View Filing |
| 10-K | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-14 | 2025-02-14 | View Filing |
| 4/A | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 8-K | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 8-K | 2024-12-13 | 2024-12-13 | View Filing |
| S-8 | 2024-11-04 | 2024-11-04 | View Filing |
| S-8 | 2024-11-04 | 2024-11-04 | View Filing |
| 10-Q | 2024-11-04 | 2024-11-04 | View Filing |
| 8-K | 2024-10-30 | 2024-10-30 | View Filing |
| 8-K | 2024-10-03 | 2024-10-03 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 8.50% | 1 | 1045 | 0 | 0.06 | 9.12 |
| Bollinger Bands Strategy | 5.64% | 1 | 173 | 0 | 0.03 | 6.26 |
| Williams PercentR Strategy | 5.18% | 1 | 462 | -0.01 | 0.04 | 5.8 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxx% | x | xx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | x | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |